364 related articles for article (PubMed ID: 26434665)
21. Safety, Immunogenicity, and Glycemic Control of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Also Using Insulin Glargine: 12-Month Results from the GEMELLI 1 Trial.
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Miossec P; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Jul; 22(7):516-526. PubMed ID: 32068436
[No Abstract] [Full Text] [Related]
22. Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.
Linnebjerg H; Lam EC; Seger ME; Coutant D; Chua L; Chong CL; Ferreira MM; Soon D; Zhang X
Diabetes Care; 2015 Dec; 38(12):2226-33. PubMed ID: 26307603
[TBL] [Abstract][Full Text] [Related]
23. Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.
Heise T; Nørskov M; Nosek L; Kaplan K; Famulla S; Haahr HL
Diabetes Obes Metab; 2017 Jul; 19(7):1032-1039. PubMed ID: 28295934
[TBL] [Abstract][Full Text] [Related]
24. A Propensity Score Matched Comparison of Brand and Biosimilar Basal Insulin in Non-Critical Hospitalized Patients with Type 2 Diabetes Mellitus.
Hu X; Zhang L; Dong C; Dong Y; Jiang J; Gao W
Adv Ther; 2019 May; 36(5):1132-1142. PubMed ID: 30900200
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study.
Derwahl KM; Bailey TS; Wernicke-Panten K; Ping L; Pierre S
Diabetes Technol Ther; 2018 Jan; 20(1):49-58. PubMed ID: 29232162
[TBL] [Abstract][Full Text] [Related]
26. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
[TBL] [Abstract][Full Text] [Related]
27. Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self-titrating insulin glargine U-100.
Hollander PA; Kiljanski J; Spaepen E; Harris CJ
Diabetes Obes Metab; 2019 Nov; 21(11):2413-2421. PubMed ID: 31264764
[TBL] [Abstract][Full Text] [Related]
28. Similar Efficacy and Safety of Basaglar
Pollom RK; Costigan T; Lacaya LB; Ilag LL; Hollander PA
Diabetes Ther; 2018 Apr; 9(2):827-837. PubMed ID: 29542012
[TBL] [Abstract][Full Text] [Related]
29. Elderly patients with diabetes experience a lower rate of nocturnal hypoglycaemia with insulin degludec than with insulin glargine: a meta-analysis of phase IIIa trials.
Sorli C; Warren M; Oyer D; Mersebach H; Johansen T; Gough SC
Drugs Aging; 2013 Dec; 30(12):1009-18. PubMed ID: 24170235
[TBL] [Abstract][Full Text] [Related]
30. Treatment satisfaction, safety, and effectiveness of biosimilar insulin glargine is comparable in patients with type 2 diabetes mellitus after switching from insulin glargine or insulin degludec: a post-marketing safety study.
Taki K; Koyanagi M; Nagaoka S; Shingaki T
Curr Med Res Opin; 2020 Dec; 36(12):1975-1983. PubMed ID: 33030354
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Kumar A; Franek E; Wise J; Niemeyer M; Mersebach H; Simó R
PLoS One; 2016; 11(10):e0163350. PubMed ID: 27760129
[TBL] [Abstract][Full Text] [Related]
32. Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR
Byrd RA; Owens RA; Blackbourne JL; Coutant DE; Farmen MW; Michael MD; Moyers JS; Schultze AE; Sievert MK; Tripathi NK; Vahle JL
Regul Toxicol Pharmacol; 2017 Aug; 88():56-65. PubMed ID: 28526658
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1).
Garg SK; Wernicke-Panten K; Wardecki M; Kramer D; Delalande F; Franek E; Sadeharju K; Monchamp T; Mukherjee B; Shah VN
Diabetes Technol Ther; 2020 Feb; 22(2):85-95. PubMed ID: 31804851
[No Abstract] [Full Text] [Related]
34. Anti-Insulin Antibodies and Adverse Events with Biosimilar Insulin Lispro Compared with Humalog Insulin Lispro in People with Diabetes.
Home P; Derwahl KM; Ziemen M; Wernicke-Panten K; Pierre S; Kirchhein Y; Garg SK
Diabetes Technol Ther; 2018 Feb; 20(2):160-170. PubMed ID: 29355435
[TBL] [Abstract][Full Text] [Related]
35. Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus.
Mishra A; Dongre S; Kulkarni G; Deshmane R; Thappa D; Ghade N; Lona J; Kokatam S; Deo A; Sonar S; Krishnan A
J Endocrinol Invest; 2024 Jun; 47(6):1435-1446. PubMed ID: 38147290
[TBL] [Abstract][Full Text] [Related]
36. A randomized crossover study of the efficacy and safety of switching from insulin glargine to insulin degludec in children with type 1 diabetes.
Urakami T; Mine Y; Aoki M; Okuno M; Suzuki J
Endocr J; 2017 Feb; 64(2):133-140. PubMed ID: 27746408
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog
Blevins TC; Raiter Y; Sun B; Donnelly C; Shapiro R; Chullikana A; Rao A; Vashishta L; Ranganna G; Barve A
BioDrugs; 2022 Nov; 36(6):761-772. PubMed ID: 36114990
[TBL] [Abstract][Full Text] [Related]
38. Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial.
Landgraf W; Owens DR; Frier BM; Bolli GB
Diabetes Obes Metab; 2024 Feb; 26(2):503-511. PubMed ID: 37860918
[TBL] [Abstract][Full Text] [Related]
39. Role of Devices in Insulin Delivery.
Meneghini LF; McNulty JN
Diabetes Technol Ther; 2017 Feb; 19(2):76-78. PubMed ID: 28118052
[No Abstract] [Full Text] [Related]
40. Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study.
Shingaki T; Taki K; Koyanagi M; Nagaoka S; Yoshizawa K; Oki N; Yoshikawa A; Imaoka T
Curr Med Res Opin; 2020 Jun; 36(6):947-958. PubMed ID: 32271092
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
